ClinicalTrials.gg

Program

BI 3802876

A development code.

In Boehringer Ingelheim's pipeline, Anti-fibrotic agent. Its studies are mostly in Liver Cirrhosis, led by Boehringer Ingelheim.

Furthest: phase 2, since Jan 7, 20262 company-led studies, 1 open or runningNext primary completion: Aug 5, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim21 open or runningphase 2since Jan 7, 2026Oct 6, 2023Aug 5, 2027phase 2 · NCT07325526
  • Named in Boehringer Ingelheim’s own pipeline as BI 3802876, phase 2, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 6, 2023First study: phase 1 study in HealthyFirst studyNCT06081530 · 59 enrolled · Belgium
  2. Jan 7, 2026Phase 2 study in Liver CirrhosisPhase 2 reachedNCT07325526 · 30 planned · United States, Canada

Ahead

  1. Aug 5, 2027Primary completion: phase 2 study in Liver CirrhosisNCT07325526

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Anti-fibrotic agent”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07325526Liver Cirrhosis · United States, Canada2RecruitingAug 5, 202730
NCT06081530Healthy · Belgium1CompletedMar 20, 202559

How it is read

Names in the registry

  • “BI 3802876”, 2 entries

Codes read as this program: BI3802876.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.